Covaxin is currently undergoing phase 3 clinical trials with 24,000 volunteers, Bharat Biotech chief said
Bharat Biotech, which has been accorded Emergency Use Authorisation from the drug regulator for its COVID-19 vaccine Covaxin, today said they are setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per year.
Denying allegations that the city-based vaccine maker lacks data of Covaxin, Krishna Ella, Chairman of Bharat Biotech, said sufficient data has already been revealed and is available on the internet.
"We have four facilities coming up. We are planning around 200 million doses (per year) in Hyderabad, 500 million doses in other cities. By 2021, we will have 700 million doses capacity... As we speak we have 20 million doses," he told reporters.
He said Covaxin is currently undergoing phase 3 clinical trials with 24,000 volunteers.
"I think we are the only company, I can categorically say, has got extensive research experience and have been extensively peer reviewed in journals. Many people say that I am not transparent in my data. I think people should have the patience to read the internet and look at what our articles are," he said on the allegations of data availability.
He said Indian companies are being targeted as inferior ones and said his company's work is not inferior than that of Pfizer's, which also came out with a vaccine for coronavirus.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)